Inflammation Before Embryo Transfer: Treat First or Proceed?

The final consultation before an embryo transfer can seem straightforward. The embryos are already frozen and the endometrium is developing as planned. A couple comes to the clinic expecting a date. The doctor pauses over a report: “This cervical test is positive. We need to treat it first, so we will postpone transfer.”

On the way home, they read the report again.

An embryo can be compared with a seed already selected for planting; the uterus is the ground being prepared. An infection in the recipient does not directly reach an embryo in stable cryostorage. The questions concern the transfer route, the reproductive tract and subsequent pregnancy. Different positive results represent different problems.

The embryo is stored; the recipient’s environment needs assessment

Embryos develop in the laboratory and are then cryopreserved. When the storage system operates correctly, a current genital infection in the recipient does not ordinarily come into direct contact with those embryos.

Transfer and pregnancy involve other considerations.

The transfer procedure

A thin catheter passes through the cervix to place the embryo in the uterine cavity. Chlamydia trachomatis and Neisseria gonorrhoeae can infect the cervix. One concern is introducing organisms into the upper tract during instrumentation. The manuscript did not identify a direct trial comparing transfer during active chlamydia with transfer after cure; this part of the discussion is based on the route of infection, rather than a measured treatment effect.

Pregnancy

A global meta-analysis of 107 studies found positive associations between chlamydia and almost all of the 12 reproductive outcomes examined in unadjusted analyses. The pooled unadjusted cohort estimates were RR 1.47 for spontaneous abortion and RR 1.28 for stillbirth.[1] Study methods and potential bias varied, limiting certainty. These are population associations, not an individual prediction.

Birth

Persistent maternal chlamydia can be transmitted during birth and cause neonatal conjunctivitis or pneumonia. CDC therefore recommends a test of cure approximately four weeks after treatment during pregnancy.[2]

What studies show after treatment

A 2022 single-centre retrospective study from the First Affiliated Hospital of Sun Yat-sen University included women with treated chlamydia and negative follow-up testing, without hydrosalpinx, and comparison women without infection.[3] The cohort included 431 women aged 20–38, including 129 in the previously infected group. Adjusted live-birth rates did not differ significantly. Clinical pregnancy was 39.5% versus 47.0%, also without a statistically significant difference.[3]

Implantation was lower in the previously infected group, 28.2% versus 36.2%, and premature rupture of membranes was more frequent, 7.8% versus 0.7%.[3] The single-centre retrospective design limits interpretation.

The study also compared intervals of ≤3 months and >3 months between a positive chlamydia test and transfer. Pregnancy outcomes did not differ significantly.[3] It did not establish a universal earliest transfer date or a requirement to wait more than three months after cure.

A delay is therefore about assessing the recipient’s condition, rather than treating an infection in the stored embryo.

A positive result can mean different things

Pre-transfer tests may include chlamydia, gonorrhoea and cultures reported under the broad heading “mycoplasma,” sometimes with an antimicrobial susceptibility panel. The organism matters more than the word “positive.”

• Confirmed infections requiring treatment: chlamydia, gonorrhoea, Mycoplasma genitalium and Trichomonas vaginalis.
• Findings requiring clinical interpretation: vaginal dysbiosis, including bacterial vaginosis, and chronic endometritis.
• Common carriage that usually does not require treatment without symptoms: Ureaplasma species and Mycoplasma hominis.

Hydrosalpinx is another important finding. It may not appear on an “inflammation” report, but its relationship to the uterine cavity needs separate assessment.

Confirmed sexually transmitted infections: treatment before transfer

These infections can be sexually transmitted and may cause few or no symptoms. Their risks differ: chlamydia and gonorrhoea can cause ascending infection; M. genitalium is associated with cervicitis and pelvic inflammatory disease; trichomoniasis primarily affects the vagina and is associated with some adverse pregnancy outcomes.[2,6]

Treatment depends on the organism. M. genitalium resistance can make treatment and follow-up more complex.

This table summarizes guidance, not a prescription. Drug selection, pregnancy status, resistance, complications and local guidance affect the actual regimen.[2,6]

Why partner management matters

Treating only one partner can be followed by reinfection. Partner assessment differs by organism: chlamydia and gonorrhoea generally involve partners from the preceding 60 days, while M. genitalium and trichomoniasis have their own requirements. For chlamydia, the abstinence period is seven days after a single-dose treatment or until completion of a seven-day regimen and symptom resolution, with partners treated. It is not a universal instruction to wait another seven days after every course.[2]

Why repeat tests need the right timing

NAATs can detect residual nucleic acid after organisms have been cleared. An early positive result therefore needs interpretation. Test-of-cure timing depends on the organism and clinical situation; testing again around three months to detect reinfection serves a different purpose.[2,6]

The timetable includes treatment, any indicated follow-up and endometrial preparation. It may mean postponing one cycle or waiting longer. Under stable cryostorage conditions, a short delay itself is generally not the main concern for embryo quality.

If the recipient is a gestational carrier

The same biological distinction applies when the embryos come from intended parents. The carrier receives appropriate treatment and indicated follow-up; partner assessment depends on the organism and exposure. The medical team then assesses readiness for transfer. A positive screening result is an opportunity to address a health issue. The useful questions concern coordinated treatment and correctly timed follow-up, rather than an automatic change of carrier.

Vaginal dysbiosis and chronic endometritis

Vaginal dysbiosis: symptoms and evidence matter

Lactobacilli commonly help maintain an acidic vaginal environment. A shift in the microbial community is called dysbiosis; bacterial vaginosis is one common form.

A meta-analysis of 17 studies involving 3,543 IVF patients found dysbiosis in approximately 18%. Early pregnancy loss was associated with dysbiosis, RR 1.71; the molecular-diagnosis subgroup also had lower clinical pregnancy rates.[4] Live birth did not differ significantly, and the certainty of evidence for all outcomes was rated very low.[4]

Symptoms such as abnormal discharge, odour or itching warrant assessment and treatment of the diagnosed condition before transfer. Whether treating an asymptomatic microbiome finding improves IVF success remains uncertain. For vaginal Candida, symptomatic infection is treated, while asymptomatic carriage generally does not require treatment.

Chronic endometritis: an endometrial assessment

A routine vaginal swab does not diagnose chronic endometritis. Hysteroscopy may suggest it, while diagnosis mainly involves endometrial biopsy and histological assessment, often with CD138 staining to identify plasma cells. Thresholds and sampling methods are not fully standardized.

A 2018 meta-analysis in women with recurrent implantation failure compared resolved with persistent endometritis after treatment. The odds ratios were 6.81 for ongoing pregnancy/live birth, 4.02 for clinical pregnancy and 3.24 for implantation.[5] These are odds ratios, not multipliers of an individual’s probability of success.

Without another indication, evidence does not support routine screening before every first transfer. Repeated implantation failure or other clinical findings can prompt discussion of endometrial assessment. ESHRE’s 2023 good practice recommendations say that assessment for chronic endometritis and antibiotic treatment after diagnosis can be considered; they do not make either a universal routine intervention.[11]

Ureaplasma and Mycoplasma hominis: common asymptomatic carriage

A result reading “Ureaplasma positive,” especially with a long susceptibility panel, can look alarming. Ureaplasma species and M. hominis are commonly found in the lower genital tract of healthy people.

The European STI Guidelines Editorial Board’s 2018 statement advises against routine testing and treatment of asymptomatic men and women for these organisms. Asymptomatic carriage is common, and evidence that routine testing and treatment do more good than harm is lacking.[7]

Repeated antibiotic courses can disrupt the microbiota and promote resistance. Fertility centres may have their own requirements; if treatment is proposed, ask what diagnosis or indication supports it. A susceptibility panel alone does not establish that prolonged treatment is necessary.

Hydrosalpinx: a separate issue before transfer

Hydrosalpinx is fluid accumulation in a blocked fallopian tube. It can follow previous pelvic infection and distal tubal scarring. Fluid may enter the uterine cavity, potentially affecting embryo retention or endometrial receptivity.

An early meta-analysis found pregnancy rates in IVF patients with hydrosalpinx to be approximately half those without it, with increased miscarriage risk.[8] The 2010 Cochrane review included five randomized trials and 646 women. Salpingectomy versus no surgery gave a Peto OR of 2.14 (95% CI 1.23–3.73) for ongoing pregnancy and an OR of 2.31 (1.48–3.62) for clinical pregnancy.[9] These odds ratios do not mean that a particular person’s pregnancy probability doubles. Proximal tubal occlusion is another option in suitable circumstances.[9]

The 2020 update included 11 trials and 1,386 women. It continued to support a benefit for clinical pregnancy, while direct live-birth data were lacking in the main salpingectomy-versus-no-surgery comparison.[12]

The Scandinavian trial found the clearest benefit among women whose hydrosalpinx was visible on ultrasound.[10] The extent of disease, one-sided or bilateral involvement, surgical feasibility and individual circumstances inform the decision. The findings do not mean that every hydrosalpinx must automatically be removed.[10]

Five questions for the next consultation

A delay can be frustrating, but its purpose should be concrete: treating a confirmed infection or addressing a relevant uterine or tubal problem, then assessing readiness for transfer. It does not guarantee success. In stable storage, the short postponement itself is usually not the main embryo-quality risk.

• Which organism or condition does the positive result identify?
• If treatment is needed, should my partner be assessed or treated, and how long should we avoid sex?
• How long is the course, is a repeat test needed, and which method and timing will be used?
• Once the clinical criteria are met, which transfer cycle could be considered?
• Is hydrosalpinx present? If there have been repeated failures or other indications, is further endometrial assessment appropriate?

The answers turn an uncertain wait into a specific clinical plan.

The embryo and the recipient both matter

People understandably focus on embryo grade, culture day and genetic testing. The recipient’s reproductive tract also needs assessment.

Confirmed infections require organism-specific treatment and follow-up where indicated. Dysbiosis and endometrial findings are interpreted against symptoms and history. Common asymptomatic carriage should not automatically be treated as disease, and hydrosalpinx needs a separate discussion. Transfer timing follows that assessment rather than a fixed calendar for every “positive” result.

Evidence table

Intervals in parentheses are 95% confidence intervals. RR is a risk ratio; OR is an odds ratio. They are not interchangeable. Observational associations do not by themselves establish causation, and odds ratios do not directly multiply personal probabilities.

Medical and image information

This is medical education, not an individual diagnosis, prescription or treatment plan. The opening consultation is a composite illustration of common situations and does not describe an identifiable patient. Treatment, testing and transfer timing require the treating team’s assessment.

The manuscript’s evidence search ended on 21 October 2026. On 2 November, the website checked follow-up conditions and OR interpretation and added the ESHRE 2023 recommendations and Cochrane 2020 update. Concept illustrations do not show actual patients, clinical events or medical imaging. The timetable infographic distinguishes organism-specific follow-up.